FKF 02SC
Alternative Names: FKF02SC; TGOF 02NLatest Information Update: 08 Jan 2016
At a glance
- Originator Unknown
- Developer Fabre-Kramer Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action 5-HT1A serotonin receptor modulators; 5-HT2C serotonin receptor antagonists; Alpha 1 adrenergic receptor antagonists; Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor modulators; Histamine H1 receptor modulators; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Schizophrenia
Most Recent Events
- 08 Jan 2016 Phase II development for Schizophrenia is ongoing in USA
- 08 Jan 2009 FKF 02SC is available for licensing (http://www.fabrekramer.com)
- 08 Jan 2009 Phase-II clinical trials in Schizophrenia in USA (PO)